Cinfina Pharma
Lead Program(s): CinFina is developing a series of mono and combination biologic therapies, CIN-109, CIN-110, CIN-209 and CIN-210, currently ranging from pre-clinical to Phase 1. The CinFina portfolio includes long-acting GLP-1’s that have the potential to transform the treatment of obesity and related cardio-metabolic diseases.
Pre-Clinical
Phase 1
Phase 2
Phase 3